Medicine provision in case of diseases of the respiratory system: opportunities and solutions
E.V. Eliseeva, V.A. Nevzorova, E.S. Maneeva, R.K. Goncharova

FGBOU IN TSMU Russian Ministry of Health, Vladivostok

Stable drug provision for patients with socially significant diseases as part of the program of state guarantees of free medical care to citizens, as well as a part of state social assistance in the form of a set of social services, is one of the domestic health care priorities. Chronic obstructive pulmonary disease (COPD) and asthma are a significant burden for society due to the continuously increasing disease incidence, the need for continuous lifelong therapy with expensive drugs and, at the same time, not the highest adherence of patients to treatment. One of the ways to increase the availability and effectiveness of drug provision for patients with asthma and COPD, as well as adherence to therapy, is the implementation of the import phase-out program. The key requirements for reproduced drugs are quality, safety, good tolerability, the availability of optimal devices for inhalation delivery, ease of use, low cost. Such requirements are met by the domestic manufacturer of medicines «Nativa». Successful implementation of the import phase-out program in the production of a full cycle of domestic medicines will allow us to confidently implement all key destinations of drug provision for all patients in need.

Key words: bronchial asthma, chronic obstructive pulmonary disease, drug supply, import phase-out, Nativa.
For citation: Eliseeva E.V., Nevzorova V.A., Maneeva E.S., Goncharova R.K. Medicine provision in case of diseases of the respiratory system: opportunities and solutions // RMJ. 2018. № 10 (I). P. 28–35.